Stay updated on Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.

Latest updates to the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page
- Check6 days agoChange DetectedThe footer revision label updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check13 days agoChange DetectedRevision history on the page updated: added v3.3.1 and removed v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRemoval of the banner about possible data delays and operating status due to funding lapses; this is a general site-wide notice and does not alter the study-specific information on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check35 days agoChange DetectedNo significant changes were detected between the two screenshots of the study page. The core study details—title, conditions, interventions, eligibility criteria, and outcome measures—remain unchanged.SummaryDifference0.4%

- Check63 days agoChange DetectedUpdated page with a government-funding status notice and an OS/operating details section, plus a version bump to v3.2.0; previous v3.1.0 reference removed.SummaryDifference4%

- Check71 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.